| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.3 | 2e-08 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.21 | 2e-07 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.19 | 4e-07 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-07 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.27 | 9e-07 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.24 | 3e-06 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.23 | 4e-06 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-06 |